WhatsApp Get a Quote

Japan MHLW Quasi-Drug vs Cosmetic Classification Traps

Published: June 16, 2026 12 min read

“`html Most suppliers think they understand the cosmetic pathway into Japan until an ingredient they have used for years suddenly requires quasi-drug approval. Formulation teams routinely assume their toothpaste, hair tonic, or skin lotion will clear customs as a cosmetic—only to learn that an active ingredient or a single efficacy claim triggers the far stricter … Read more

“`html

Most suppliers think they understand the cosmetic pathway into Japan until an ingredient they have used for years suddenly requires quasi-drug approval. Formulation teams routinely assume their toothpaste, hair tonic, or skin lotion will clear customs as a cosmetic—only to learn that an active ingredient or a single efficacy claim triggers the far stricter quasi-drug route under Japan’s Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act). The regulatory shock is expensive. This article maps the specific ingredient-triggered switches that force products across the line, because that is where English-language guides fall short.

Why Japan’s Quasi-Drug Classification System Catches Foreign Suppliers Off Guard

Japan does not treat quasi-drugs as a subcategory of cosmetics. They are a separate regulated category under the PMD Act, governed by the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA). This distinction matters operationally: cosmetics operate on a notification-based system, while quasi-drugs require pre-market approval covering corporate review, manufacturing procedures, and facility inspection before any commercial shipment.

A product can shift from cosmetic to quasi-drug status if it carries designated active ingredients or makes efficacy claims consistent with quasi-drug definitions. Many foreign suppliers discover this mismatch only during the import and regulatory review stage, when PMDA identifies the product as requiring quasi-drug approval rather than cosmetic notification. The PMDA’s official guidance on quasi-drug manufacturing and marketing procedures is explicit: regulatory review covers corporate review and approval procedures before market entry, meaning cosmetic-notification workflows are insufficient for quasi-drugs.

What makes this particularly difficult is that ingredient lists do not come with classification warnings. A formulation that is cosmetic-compliant in the EU or US may contain actives that MHLW has designated as quasi-drug ingredients. The supplier has not changed their product; Japan’s classification framework has changed its regulatory fate. The European Business Council in Japan has noted that ingredient rules differ between Europe and Japan, and that an ingredient permitted in cosmetics elsewhere may require approval under Japan’s quasi-drug framework.

MHLW distinguishes quasi-drugs from ordinary cosmetics by requiring approved efficacy-related treatment or prevention purposes and specific regulatory examination. That examination is not a formality—it involves review of facilities, equipment, and quality-control systems, plus equivalency checks against previously approved items. For suppliers accustomed to the EU’s cosmetics notification model or FDA’s OTC drug monograph system, this process represents unfamiliar territory.

How MHLW Defines the Line Between Cosmetics and Quasi-Drugs

The regulatory boundary rests on two pillars: ingredients and claims. Cosmetics under the PMD Act are limited to mild, appearance-related claims and notification-based compliance. Quasi-drugs require designated active ingredients, efficacy-related purposes (typically prevention or treatment of specific conditions), and pre-market approval from PMDA. This is not a spectrum; it is a threshold that, once crossed, changes every subsequent compliance obligation.

MHLW’s quasi-drug system requires that products demonstrate approved efficacy-related treatment or prevention purposes. The “prevention” language is especially relevant for personal care. A cosmetic moisturizer can claim to hydrate skin. A quasi-drug can claim to prevent acne, prevent dandruff, or prevent hair loss—provided it contains the designated active ingredient at approved concentrations and clears regulatory examination.

The PMDA’s manufacturing and marketing procedure guidance reinforces this distinction: approval by authorities is required before market entry. This is not parallel to cosmetic notification, where a company files documentation and may proceed. For quasi-drugs, the authority must grant approval before manufacture or import for sale begins.

Some companies attempt to thread this needle by softening marketing claims while retaining active ingredients at pharmacologically relevant concentrations. This approach misunderstands how classification works. When MHLW has designated a specific active ingredient for quasi-drug use, the presence of that ingredient at relevant concentrations—combined with product positioning in a quasi-drug category such as medicated toothpaste or anti-hair-loss tonic—can trigger classification obligations, even if the marketing language is mild. The ingredient list is not neutral territory; it functions as a regulatory declaration. That said, classification ultimately depends on the combination of ingredient, concentration, product category, and intended use—not on any single factor in isolation.

Oral Care Ingredients That Trigger Quasi-Drug Classification in Japan

Oral care is where classification failures occur most predictably. The category sits at the intersection of hygiene and treatment, and MHLW has designated numerous oral care actives as quasi-drug ingredients. Understanding this boundary is critical for suppliers working in oral care ingredient formulation.

Medicated toothpastes (薬用歯みがき類) and mouthwashes containing designated actives for caries prevention, periodontal disease prevention, or bad breath suppression fall under quasi-drug requirements. The specific actives are listed in MHLW’s quality standards for quasi-drug ingredients—the 2022 update published specifications for 2,647 ingredients and additives (Japanese Standards of Quasi-drug Ingredients, or JSQI). The pattern is consistent: any ingredient with recognized pharmacological action for oral disease prevention or treatment pushes the product out of cosmetic territory.

Fluoride compounds for caries prevention are the most commonly encountered example. Sodium fluoride (フッ化ナトリウム) and sodium monofluorophosphate at concentrations designated for anti-caries efficacy are quasi-drug actives in Japan. But the trigger extends beyond fluoride. Ingredients targeting gingival inflammation reduction (such as certain glycyrrhizin derivatives), tartar control with therapeutic intent, or dentinal hypersensitivity treatment with nerve-blocking mechanisms (such as potassium nitrate at pharmacological concentrations) can all trigger quasi-drug status. A formulation team may see “toothpaste with botanical extract” and assume cosmetic classification; MHLW sees an active with anti-inflammatory pharmacology at a concentration matching quasi-drug specifications and classifies accordingly.

The 2021 MHLW updates to the JSQI introduced new quasi-drug application rules, a revised permitted additives list, and reclassified medicated oral-care products into three distinct classes. These changes materially altered formulation strategy for medicated oral care products targeting the Japanese market. Suppliers who had relied on previous ingredient tolerances found their existing formulations subject to reclassification. Japan’s quasi-drug regulation does not grandfather previous formulations; each product is evaluated against current standards at the time of application.

What complicates oral care specifically is that many markets treat therapeutic toothpaste as either cosmetic or over-the-counter drug. The quasi-drug category is unfamiliar to most international suppliers. Japanese importers sometimes assume their supplier understands the distinction; the supplier assumes Japanese regulation mirrors EU or FDA frameworks. Both assumptions fail, and the product stalls during regulatory review.

Hair Care and Personal Care Ingredients on the Quasi-Drug Boundary

Hair care presents its own cluster of classification triggers. Anti-hair-loss products (育毛剤) are quasi-drugs when they contain designated actives at specified concentrations. The Japanese hair care and scalp treatment market is substantial, reflecting strong consumer demand in aging-related categories, and PMDA scrutiny of anti-hair-loss quasi-drugs has remained consistently high.

The classification mechanism is straightforward. A shampoo that cleans hair is cosmetic. A shampoo or tonic containing an active ingredient designated to prevent hair loss, stimulate hair growth, or treat scalp conditions is quasi-drug. The same physical product faces a different regulatory pathway, determined by ingredient pharmacology, concentration, and intended use.

Hair dyes and permanent wave products occupy related territory. The 2021 JSQI amendments specifically affected these categories, changing formulation strategy requirements. Oxidative hair dyes with certain active concentrations and permanent wave agents with specific chemical actions fall into quasi-drug classification depending on exact formulation parameters. Suppliers unfamiliar with cosmetic and quasi-drug regulatory boundaries in Japan frequently misjudge these products.

Skin-lightening products (美白) represent another high-scrutiny area. Ingredients that suppress melanin production through tyrosinase inhibition—such as ascorbyl glucoside (a stable vitamin C derivative), kojic acid, arbutin, or tranexamic acid at designated concentrations—cross into quasi-drug territory when MHLW has recognized their pharmacological mechanism and designated them as quasi-drug actives. Published research confirms that kojic acid and vitamin C derivatives function as tyrosinase modulators, supporting their classification as pharmacologically active rather than merely cosmetic.

Acne prevention and treatment products follow the same pattern. A cosmetic can claim to cleanse skin or maintain skin condition. A product with an active ingredient designated for acne prevention or treatment—salicylic acid (サリチル酸) at certain concentrations, specific antimicrobial agents such as isopropyl methylphenol—requires quasi-drug approval when formulated and marketed for that purpose.

Personal care suppliers often do not know their own ingredients’ regulatory status in Japan. They know the INCI name, the supplier’s recommended use level, and the EU and FDA positions. They may not know whether MHLW has designated that exact compound as a quasi-drug active at the concentration used in their formulation. This knowledge gap is the classification trap in practice.

The Quasi-Drug Approval Process: Timelines, Costs, and Documentation

Once a product is identified as requiring the quasi-drug pathway, the procedural reality changes fundamentally. Quasi-drug approvals for products matching established profiles (前例品, precedent products) typically take 6–8 months. Products with new active ingredients not previously approved in any quasi-drug can take significantly longer—potentially years—due to the full pharmacological and toxicological review MHLW requires for substances without established Japanese regulatory history.

The PMDA’s official guidance specifies that regulatory review covers the applicant entity itself, not merely the product formulation. Manufacturing and import/sales licensing involves examination of facilities, equipment, and quality-control systems, including GMP compliance verification. For foreign suppliers without a Japanese subsidiary, this typically requires a designated marketing authorization holder (MAH) in Japan who becomes the regulatory representative for the application.

Documentation requirements extend well beyond formulation disclosure. MHLW’s licensing and approval system includes review of compliance with quality standards and disqualification checks. The equivalency review (前例品との比較)—determining whether a product is equivalent to already approved items—can streamline the process for formulations matching established quasi-drug profiles. Novel actives or unusual formulations face deeper examination, potentially including Japanese-market-specific stability and safety testing.

Costs scale with complexity. Direct PMDA fees are only part of the picture. The MAH arrangement, facility compliance documentation, stability testing to Japanese standards, potential reformulation to match approved ingredient specifications, and Japanese-language dossier preparation all accumulate. For a supplier that expected to ship under cosmetic notification, this represents unbudgeted regulatory investment that can exceed initial market-entry projections.

Labeling and Marketing Claim Restrictions by Classification

Classification determines what can appear on the package and in promotional materials. Suppliers who attempted to soften claims to avoid quasi-drug status face a second problem: even if they cleared import as a cosmetic, their labeling might overstep cosmetic permissions. And if classified as a quasi-drug, labeling must conform to quasi-drug-specific requirements.

Quasi-drugs must carry approved efficacy claims (効能効果), not aspirational marketing language. The claim “prevents dandruff” (フケを防ぐ) is permissible for an approved anti-dandruff quasi-drug; “refreshes scalp” on the same formulation might understate the product’s regulated status, while “treats seborrheic dermatitis” would overstate it into drug territory. The claim vocabulary is constrained in both directions.

Cosmetics face the opposite restriction: they cannot imply pharmacological action. “Whitening” (美白) in some markets suggests cosmetic brightening; in Japan, it can trigger quasi-drug classification depending on the implied mechanism. “Anti-aging” is permissible for cosmetics if limited to moisturizing or appearance-related claims, but crosses the line if suggesting physiological reversal of aging processes.

Ingredient disclosure requirements also diverge. Quasi-drugs must list active ingredients (有効成分) separately from other components (その他の成分), with established Japanese names and approved concentrations. Cosmetic labeling follows different conventions. A supplier using dual-purpose packaging for multiple markets risks Japanese non-compliance if the label format assumes EU or US conventions.

Japanese regulatory enforcement does not accommodate creative interpretation of label language. PMDA and MHLW review labeling during the approval process for quasi-drugs, and post-market surveillance identifies violations for both categories. Consequences can include product recall, import suspension, and reputational damage with Japanese distributors who bore the compliance risk. For suppliers working across international regulatory frameworks, understanding these distinctions before market entry is essential.

Practical Strategies for Choosing the Right Regulatory Pathway

The first strategic decision is intentional classification rather than accidental discovery. Suppliers should audit their ingredient lists against MHLW’s designated quasi-drug actives before finalizing formulations for Japan. The 2022 JSQI covering 2,647 ingredients provides the reference framework, though navigating it effectively requires regulatory expertise or qualified local consultation with specialists familiar with PMDA procedures.

For oral care specifically, the choice is often binary: reformulate to exclude quasi-drug actives and accept cosmetic-level claims, or commit to the quasi-drug pathway from formulation inception. Half-measures—keeping the active ingredient while softening claims—create regulatory risk without commercial benefit. A toothpaste containing fluoride at anti-caries concentrations is a quasi-drug candidate regardless of how the marketing copy reads.

For hair care and skin care, the calculation includes market positioning. Products competing in the anti-hair-loss or skin-lightening segments derive commercial value precisely from quasi-drug claims. Stripping those claims to achieve cosmetic classification may eliminate the product’s competitive rationale. In these cases, building the quasi-drug approval timeline into market-entry planning—rather than treating it as an obstacle—is the more effective strategy.

MAH selection deserves early attention. The Japanese marketing authorization holder is not a passive intermediary; they bear regulatory responsibility for the product’s compliance. Selecting an MAH with direct experience in the specific quasi-drug category (oral care, hair care, skin care) reduces review friction and improves approval predictability. Suppliers should evaluate MAH candidates on their track record with PMDA, not merely on cost or logistics capability.

Pre-submission consultation with PMDA is available and underutilized by foreign suppliers. These consultations can clarify classification ambiguity before the full application is submitted, reducing the risk of mid-process reclassification or rejection. The cost of consultation is marginal compared to a failed or delayed approval.

Finally, suppliers should treat Japan’s quasi-drug framework as a market access tool rather than a barrier. Quasi-drug approval, once obtained, provides regulatory credibility that cosmetic classification does not. Japanese consumers and distributors recognize quasi-drug status as a quality signal. The investment in approval creates a competitive moat that notification-only competitors cannot replicate.

References

Disclaimer

This article is for informational purposes only. LLRNCARE makes no representations or warranties about the completeness, accuracy, or reliability of the information. Any reliance is at your own risk.

For professional dental advice, consult a qualified dental professional. For regulatory compliance, consult legal experts.

“`